Our study illustrates that a relatively small percentage of myeloid malignancies (10–13%) would be susceptible to SLC16A1 inhibition, but highlights phenotypic drug screening as attractive means of identifying responding cells/patients harboring metabolic dependencies. Here, SLC16A1 is linked to myeloid neoplasm.